Arcturus adds $50M Meiji investment as Q3 pipeline milestones stay on track
Meiji Seika Pharma bought a stake in Arcturus at a premium to fund OTC deficiency work and validate the LUNAR 2.0 platform, layered onto Q3 trial updates.
SEC filing (5)
3 stories
Meiji Seika Pharma bought a stake in Arcturus at a premium to fund OTC deficiency work and validate the LUNAR 2.0 platform, layered onto Q3 trial updates.
SEC filing (5)
Kodiak said both Phase 3 DAYBREAK arms hit their primary endpoints, with a Zenkuda BLA planned by year end and KSI-101 topline data due in December.
SEC filing (2)
Alector plans an October 13 webinar on its anti-Abeta, tau, and alpha-synuclein programs following its $100 million upfront Genentech license and updated cash guidance into 2029.
SEC filing (5)